Form 4: Rhythm Pharma CEO Granted 179,750 Equity Awards

Rhythm Pharmaceuticals' President and CEO, David P. Meeker, was granted 71,900 restricted stock units and 107,850 stock options on February 11, 2026, as part of his compensation.

Summary

• David P. Meeker, President and CEO of Rhythm Pharmaceuticals, Inc. (RYTM), was granted new equity awards.
• On February 11, 2026, Meeker acquired 71,900 Restricted Stock Units (RSUs).
• These RSUs vest in four equal annual installments of 25% each, starting on February 1, 2027, and continuing through February 1, 2030.
• Also on February 11, 2026, Meeker acquired 107,850 stock options with an exercise price of $98.47.
• The stock options have an expiration date of February 10, 2036.
• The options vest in 16 substantially equal quarterly installments based on continuous service following the grant date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued commitment to executive retention and aligns management's interests with long-term shareholder value, which is generally well-received by investors.

Positives

• Grant of significant equity awards (71,900 RSUs and 107,850 stock options) aligns the CEO's interests with long-term shareholder value.
• The vesting schedules for both RSUs and stock options incentivize continued service and performance over several years.

Future Outlook

The filing details future vesting schedules for both restricted stock units and stock options, indicating a long-term incentive structure for the CEO. The RSUs will vest annually from February 2027 to February 2030, and the stock options will vest quarterly over four years following the grant date.

Industry Context

StockSavvy.ai notes that equity grants to executive leadership, such as those reported for David P. Meeker, are a standard practice in the biotechnology and pharmaceutical industries. These grants are typically designed to align executive incentives with long-term shareholder value creation, especially in companies like Rhythm Pharmaceuticals that are focused on drug development and commercialization, where long development cycles are common.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of these equity grants, combining Restricted Stock Units (RSUs) and stock options with multi-year vesting schedules, is consistent with executive compensation practices at comparable biopharmaceutical companies.
• For instance, companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals often utilize similar long-term incentive plans to retain key talent and motivate performance over extended periods.
• The specific number of units and options granted would typically be benchmarked against peer group compensation data, considering the company's market capitalization, performance, and the executive's role and tenure.

Related Party Transactions

• The equity grants to David P. Meeker are a form of related party transaction (compensation to an executive), but they are standard and disclosed as required.

Stakeholder Impact

• Shareholders: The grants aim to align the CEO's interests with long-term shareholder value, potentially leading to more sustained growth and performance.
• Employees: No direct impact on general employees is indicated, but a stable leadership team can positively influence company culture and direction.
• Management: The grants provide significant long-term incentives for the CEO, encouraging continued dedication and strategic execution.

Next Steps

• David P. Meeker will continue to serve as President and CEO, with his compensation tied to the vesting schedules of these equity awards.
• The company will continue its operations, with the CEO's incentives aligned with long-term performance.

Key Dates

Recommendation

This Form 4 filing reports a routine executive equity grant, which is a standard part of compensation packages designed to align management incentives with shareholder interests. It does not contain new operational or financial information that would fundamentally alter the investment thesis for Rhythm Pharmaceuticals. Therefore, a "hold" recommendation is appropriate, as this filing alone does not provide a basis for a significant change in investment strategy, but rather confirms ongoing executive compensation practices.

Keywords

Rhythm Pharmaceuticals, RYTM, David P Meeker, Restricted Stock Units, Stock Options, Equity Grant, Insider Transaction, CEO Compensation, Form 4, Executive Compensation